» Articles » PMID: 31966039

Biology and Pathogenesis of Human Osteosarcoma

Abstract

Osteosarcoma (OS) is a bone tumor of mesenchymal origin, most frequently occurring during the rapid growth phase of long bones, and usually located in the epiphyseal growth plates of the femur or the tibia. Its most common feature is genome disorganization, aneuploidy with chromosomal alterations, deregulation of tumor suppressor genes and of the cell cycle, and an absence of DNA repair. This suggests the involvement of surveillance failures, DNA repair or apoptosis control during osteogenesis, allowing the survival of cells which have undergone alterations during differentiation. Epigenetic events, including DNA methylation, histone modifications, nucleosome remodeling and expression of non-coding RNAs have been identified as possible risk factors for the tumor. It has been reported that p53 target genes or those genes that have their activity modulated by p53, in addition to other tumor suppressor genes, are silenced in OS-derived cell lines by hypermethylation of their promoters. In osteogenesis, osteoblasts are formed from pluripotent mesenchymal cells, with potential for self-renewal, proliferation and differentiation into various cell types. This involves complex signaling pathways and multiple factors. Any disturbance in this process can cause deregulation of the differentiation and proliferation of these cells, leading to the malignant phenotype. Therefore, the origin of OS seems to be multifactorial, involving the deregulation of differentiation of mesenchymal cells and tumor suppressor genes, activation of oncogenes, epigenetic events and the production of cytokines.

Citing Articles

Single-cell RNA sequencing revealed PPARG promoted osteosarcoma progression: based on osteoclast proliferation.

Sun L, Zhang J, Xiahou Z, Zhao Z, Liang Y Front Immunol. 2025; 15:1506225.

PMID: 39936154 PMC: 11810940. DOI: 10.3389/fimmu.2024.1506225.


Development and pan-cancer validation of an epigenetics-based random survival forest model for prognosis prediction and drug response in OS.

Yin C, Chi K, Chen Z, Zhuang S, Ye Y, Zhang B Front Pharmacol. 2025; 16:1529525.

PMID: 39925852 PMC: 11803151. DOI: 10.3389/fphar.2025.1529525.


PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs.

Dziubek K, Faktor J, Lokhande K, Shrivastava A, Papak I, Chrusciel E Cell Commun Signal. 2024; 22(1):605.

PMID: 39696578 PMC: 11658327. DOI: 10.1186/s12964-024-01935-w.


Tellurium-Doped Bioactive Glass Induces Ferroptosis in Osteosarcoma Cells Regardless of FSP1.

Panczyszyn E, Lallukka M, Gagliardi M, Saverio V, Monzani R, Miola M Antioxidants (Basel). 2024; 13(11).

PMID: 39594469 PMC: 11591201. DOI: 10.3390/antiox13111327.


Make it STING: nanotechnological approaches for activating cGAS/STING as an immunomodulatory node in osteosarcoma.

ODonoghue J, Freeman F Front Immunol. 2024; 15:1403538.

PMID: 39403376 PMC: 11471590. DOI: 10.3389/fimmu.2024.1403538.


References
1.
Komori T . Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem Cell Biol. 2018; 149(4):313-323. DOI: 10.1007/s00418-018-1640-6. View

2.
Denduluri S, Wang Z, Yan Z, Wang J, Wei Q, Mohammed M . Molecular pathogenesis and therapeutic strategies of human osteosarcoma. J Biomed Res. 2015; 30. DOI: 10.7555/JBR.29.20150075. View

3.
Klein M, Siegal G . Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006; 125(4):555-81. DOI: 10.1309/UC6K-QHLD-9LV2-KENN. View

4.
Zhang H, Mao J, Hu W . Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations. Med Sci Monit. 2019; 25:1307-1313. PMC: 6391859. DOI: 10.12659/MSM.915001. View

5.
Deng R, Zhang J, Chen J . lncRNA SNHG1 negatively regulates miRNA‑101‑3p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma. Int J Mol Med. 2018; 43(3):1157-1166. PMC: 6365036. DOI: 10.3892/ijmm.2018.4039. View